Clinical Trials · NCT00543179

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Name: Treatment of the Dumping Syndrome With Lanreotide Autogel®
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownPhase 4Lanreotide

Phase: Phase 4
Recruitment status: Unknown
Sponsor: Radboud University Medical Center
Enrollment: 0
Start date: Oct 2007
Locations: 1 site, Netherlands
Primary endpoint: Responses to the dumping provocation test. Effectiveness is defined as a heart rate increase of ≤ 10 beats/min and a negative breath-hydrogen test after glucose provocation test.

View Lanreotide compound reference